Look at the forefront of view
February 21, 2024, Stanford Universitys 亓 Lei Team The top international academic journal Cell published on the CELL: A Versatile Crispr-Cas13D PLATFORM for Multiplexed Transcriptomic Regulation and Metabolic Engineering in Primary Human T Cells.Thesis link: https://www.cell.com/cell/fulltext/s0092-8674 (13) 00211-0
CAR-T cell therapy has completely changedCancer treatment pattern, especially in treating blood cancer. With the development of CRISPR-CAS9 gene editing technology, the next generation of gene engineering T cell therapy shows potential cancer treatment effects.However, the CRISPR-CAS9 gene editing system still has restrictions in terms of security, effectiveness, and wider application. CAS9 nucleic acid enzymes and base editors permanent changes to T cell genome and potential gene toxic side effects are one of the current challenges.
In this context, the research has developed a multi-RNA editing platform based on CRISPR-CAS13D- Mega Multiple transcriptional regulation and metabolic engineering.The research and development of multiple effects orientation arrays (MEGA), which is a programmable and scalable platform that uses CRISPR-CAS13D RNA guidance and RNA targeted activity to regulate T cells in the transcription level.MEGA can achieve quantitative, reversible, and large -scale gene knocks low in human T cells without a targeted or cut genome DNA.
Apply MEGA to CAR-T cell exhaustion model, to screen the combination of CRISPRfactor. In addition, the study also realizes the control of drugs to control CAR activation through FDA -approved drug -to -piopyrazine regulatory MEGA.Finally, MEGA realizes multiple blocking of immunomically regulating metabolic pathways to enhance the in vitro and body adaptability and anti-tumor activity of CAR-T cells.
Technical value observation
MEGAs various T cellsEngineering applications and solve the key restrictions of CRISPR-CAS9 gene editing technology in CAR-T cell therapy.As a synthetic immunology toolkit, MEGA provides T cells with the ability to apply various applications from basic biology to enhancing cancer immunotherapy.
This result is currently in the upstream link of the industrial chain.From the perspective of the overall industry chain, unlike other industries, the upstream of the gene editing industry is usually not an enterprise, but a research team such as scientific research institutions, colleges and universities, etc. These research teams authorize patents to midstream biotechnology companies. At the same time, biotechnology, biotechnology, biotechnology.The company shares patents by investing in scientific research teams.The middle reaches of biotechnology companies can be divided into two categories, one is gene editing product suppliers, and the other is gene editing technology service providers. Product suppliers referRelated technology platforms are usually provided.The downstream terminal customers mainly include CRO companies, pharmaceutical companies, biotechnology companies, and scientific research institutions.Generally, biotechnology companies provide products and technologies for these downstream companies. Correspondingly, downstream companies will invest in biotechnology companies or cooperate with them to share products.
Macro market observation
gene editing technologyGeography
From the perspective of gene editing technology, the development of gene editing technology route has gone through ZFN technology, TALEN technology, and CRISPR/CAS technology.From the perspective of technical advancedness and convenience, with the gradual improvement of technical updates, in terms of technological cytotoxicity and technical difficulty, technology has gradually decreased with the update of technology.
Summary of investment and financing and mergers and reorganization of China gene editing industry
The market size forecast of the global gene editing industry
According to Statista, from 2023 to 2030, global gene editingThe market size of the industry will grow at a compound growth rate of 22.3%. In 2023, the market size will be about US $ 6.619 billion. By 2030, it is expected to reach US $ 36.061 billion.
Chinese gene editing technology track thermal map
The forward -looking industry thermal map shows that areas that are strongly related to the key technologies of gene editing include Beijing -Tianjin -Hebei regions, Central China, and the Guangdong -Hong Kong -Macao Greater Bay Area. According to the number of enterprises, Henan Province may become a key development area in the industry. TheseThe urban agglomeration has invested a large number of policies, funds, environment and talent resources for gene editing research and development, and has become a potential gene editing technology development center.According to the heat map, there is great possibility that the North China region has become a pilot area for gene editing technology.Focus on related enterprises in Shenqiu County, Zhoukou City, Henan Province, Wanzai County, Yichun City, Jiangxi Province, Shenzhen Nanshan District, Shenzhen City, Haidian District, Beijing, and Xicheng District, as well as the investment environment and investment environment and the development of the gene editing industryPotential market.
Prospective Economist App Information Group
For more industry research and analysis, please refer to forward-lookingThe Industrial Research Institutes "China Gene Report Market Prospects and Investment Strategic Planning Analysis Report"
At the same time, the Industrial Research Institute also provides industrial big data, industrial research reports, industrial planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, park planning, and park planning, park planning, park planning, park planning, park planning, park planning, and park planning,Industry investment, industrial maps, smart investment systems, industry status certificates, IPO consultation/recruitment and research, IPO work cards and other solutions.In any public information disclosure of the prospectus, the companys annual report and other public information disclosure, the content of this article is required to obtain the regular authorization of the forward -looking Industrial Research Institute.
